oth trials, with at least half surviving for 14 months with no detectable sign of cancer recurrence.

The researchers involved a pancreatic cancer line that spreads swiftly, in one test. They say that live imaging showed that in control mice the cancer spread to the liver, spleen, kidneys, bladder, lungs, bone, and intestines. But mice treated with the CMV BikDD showed only a few small tumours in nearby organs.

There were no detectable metastases in mice treated with the VISA-BikDD combination.

"All cancer drugs have some toxicity and so cause side effects, which affects the dose that can be administered. The VISA-BikDD produces virtually no systemically acute toxicity or acute pancreatitis," the authors report.

Dr. Abbruzzese says that the phase I clinical trial will advance under a National Cancer Institute Specialized Programs of Research Excellence (SPORE) grant in pancreatic cancer. SPORE awards are designed to translate scientific findings into the clinic.

"There are no good options for pancreatic cancer patients now. That's why we are trying new approaches such as this one as part of SPORE," says Dr. Abbruzzese.


'"/>




Page: 1 2
Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis